



Generic and Biosimilar Medicines Save Georgia Patients Billions

In 2022, patients and the state of Georgia saved \$13.2 billion through generic and biosimilar medicines. Generic and biosimilar competition drives prices down, but meaningful action is needed to give patients the full value of lower-priced generic and biosimilar medicines.

See how the savings add up in Georgia

Generics and biosimilars save money and increase access for patients and payers.



MEDICARE SAVINGS
\$3.9 BILLION

MEDICARE SAVINGS PER ENROLLEE
\$2,750

TOTAL SAVINGS	BIOSIMILARS FACTS
 The U.S. health care system has saved more than \$2.9 trillion in the last 10 years through affordable generics and biosimilars.	 On average, biosimilar sales prices are more than 50% lower than the reference product's price was at the time of biosimilar launch.
 New generics and biosimilars are increasingly contributing savings – from \$6 billion in 2015 to 20 times that: \$116 billion in 2022.	 Use of biosimilars generated more than \$23 billion in savings since 2015.
 AARP reports that nearly 80% of generic drugs commonly used by seniors decreased in price, most by 10% to 50%.	 Because of biosimilars, patient access to care has increased by more than 344 million days of therapy.
 During the past five years, the total value of generic sales, including new launches and increased volume, has fallen by more than \$6.4 billion.	

Overall U.S. Savings

Generics and Biosimilars Savings in 2022: \$408 Billion

Generics represent **90%** of prescriptions filled, yet account for only **17.5%** of drug spending.



Average generic copay

\$6.16



Average brand drug copay

\$56.12

Share of Health Care Spending

